Literature DB >> 25301472

Dexmedetomidine and ketamine combination for a patient with xeroderma pigmentosa.

Rakhee Goyal1,2, Mubashir Syed Islam3.   

Abstract

Patients of xeroderma pigmentosa (XP) have increased sensitivity to ultraviolet light and a defective nucleotide excision repair (NER) mechanism in their DNA. Several types of neurological, dermatological, and ophthalmological complications are common in these patients. There is increasing evidence of delayed recovery and worsening of neurological status following general anesthesia in such patients. Some reports have shown uneventful conduct of total intravenous anesthesia in patients of XP. The authors report a case of XP in a young girl for surgery, previously anesthetized with delayed recovery, managed successfully with a combination of intravenous dexmedetomidine and ketamine.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25301472     DOI： 10.1007/s00540-014-1928-1

Source DB:  PubMed          Journal:  J Anesth        ISSN： 0913-8668            Impact factor:   2.078


  10 in total

Review 1.  Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology.

Authors:  Joseph D Tobias
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

2.  Anaesthetic management of patients with Xeroderma pigmentosum. A series of three cases.

Authors:  G S Shrestha; R P Sah; A G Amatya; N Shrestha
Journal:  Nepal Med Coll J       Date:  2011-09

3.  [Anesthesia for a patient with xeroderma pigmentosum].

Authors:  Yoshiki Masuda; Hitoshi Imaizumi; Mioko Okanuma; Eichi Narimatsu; Yasufumi Asai; Akiyoshi Namiki
Journal:  Masui       Date:  2002-02

4.  Comparison of genotoxicity of sevoflurane and isoflurane in human lymphocytes studied in vivo using the comet assay.

Authors:  L Karabiyik; S Sardaş; U Polat; N A KocabaS; A E Karakaya
Journal:  Mutat Res       Date:  2001-05-31       Impact factor: 2.433

5.  DNA strand breaks in cells with DNA repair deficiency after halothane exposure in vitro.

Authors:  M Reitz; E Lanz
Journal:  Arzneimittelforschung       Date:  1993-04

6.  Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases.

Authors:  K H Kraemer; M M Lee; J Scotto
Journal:  Arch Dermatol       Date:  1987-02

Review 7.  The 8,5'-cyclopurine-2'-deoxynucleosides: candidate neurodegenerative DNA lesions in xeroderma pigmentosum, and unique probes of transcription and nucleotide excision repair.

Authors:  P J Brooks
Journal:  DNA Repair (Amst)       Date:  2008-05-20

8.  [Anesthesia in patient with Xeroderma Pigmentosum: case report.].

Authors:  Carlos Rogério Degrandi Oliveira; Luciana Elias; Ana Cláudia de Melo Barros; Diogo Brüggemann da Conceição
Journal:  Rev Bras Anestesiol       Date:  2003-02       Impact factor: 0.964

9.  [Anesthesia for a patient with xeroderma pigmentosum].

Authors:  Ryohei Miyazaki; Taro Nagata; Tetsuya Kai; Shosuke Takahashi
Journal:  Masui       Date:  2007-04

10.  Postoperative neurological aggravation after anesthesia with sevoflurane in a patient with xeroderma pigmentosum: a case report.

Authors:  Salaheddine Fjouji; Mustapha Bensghir; Bahija Yafat; Najib Bouhabba; Elhoucine Boutayeb; Hicham Azendour; Nordine Drissi Kamili
Journal:  J Med Case Rep       Date:  2013-03-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.